Chattanooga Oncology Hematology Associates

Summary

Chattanooga Oncology Hematology Associates is a medical facility located in Chattanooga, Tennessee. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Pancreatic Cancer and other specialties. Chattanooga Oncology Hematology Associates is involved with conducting 129 clinical trials across 109 conditions. There are 6 research doctors associated with this hospital, such as Meredith A McKean, Vijay Patel, Brooke Daniel, M.D., and Edward Arrowsmith.

Top PIs

Clinical Trials running at Chattanooga Oncology Hematology Associates

Cancer

Lung Cancer

Myelofibrosis

Non-Small Cell Lung Cancer

Colorectal Cancer

Chronic Lymphocytic Leukemia

Lymphoma

Melanoma

Multiple Myeloma

Myelodysplastic Syndrome

LY3537982 + Immunotherapy/Chemotherapy

for Non-Small Cell Lung Cancer

This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.

Recruiting

1 award

Phase 3

14 criteria

Vepugratinib

for Bladder Cancer

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

Recruiting

1 award

Phase 3

3 criteria

LY3537021

for Nausea and Vomiting from Chemotherapy

The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.

Recruiting

0 awards

Phase 2

2 criteria